Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand

Romanee Chaiwarith, Jutarat Praparattanapan, Khanuengnit Nuket, Wilai Kotarathitithum, Khuanchai Supparatpinyo, Romanee Chaiwarith, Jutarat Praparattanapan, Khanuengnit Nuket, Wilai Kotarathitithum, Khuanchai Supparatpinyo

Abstract

Background: After the global implementation of national immunization programs for prevention of measles, mumps, and rubella (MMR), the prevalences of protective antibodies to these viruses are high in general population. However, there are limited data among human immunodeficiency virus (HIV)-1 infected individuals. This study aimed to determine the seroprevalence of antibodies to these viruses, and the serologic responses after vaccination among HIV-infected adults in Northern Thailand.

Methods: A cross-sectional study was conducted in 500 HIV-infected adults, aged 20-59 years, receiving combination antiretroviral therapy, CD4 cell count ≥200 cells/mm(3), and plasma HIV-1 RNA <50 copies/mL, and 132 HIV-uninfected controls, aged 20-59 years, at Chiang Mai University Hospital during July and August 2011. Prevalences of protective antibodies to these viruses as well as serologic responses after MMR vaccination in those without protective antibody to at least one of the three viruses were compared between groups.

Results: The prevalences of protective antibodies to measles, mumps, and rubella were 94.2, 55.0, and 84.6 % among HIV-infected adults, and 97.7, 67.5, and 89.4 % among HIV-uninfected controls, respectively. The prevalence of protective antibody to mumps was significantly lower in HIV-infected adults (p-value = 0.010). MMR vaccination was done in 249 HIV-infected and 46 HIV-uninfected controls; at week 8 to 12 after vaccination, the seroprotective rates against measles, mumps, and rubella in HIV-infected adults were 96.4, 70.7, and 98.0 %, respectively, whereas those in HIV-uninfected controls were 100, 87, and 100 %, respectively. No serious adverse effects were observed.

Conclusions: In contrast to measles and rubella, the prevalence of protective antibody to mumps was low in both HIV-infected adults and HIV-uninfected controls in northern Thailand. The seroprotective rates after MMR vaccination in both groups were considerably high, except only for mumps. Therefore, MMR vaccination should be considered in all HIV-infected adults receiving antiretroviral therapy with undetectable plasma HIV-1 RNA and CD4 cell count ≥200 cells/mm(3).

Trial registration: ClinicalTrials.gov: NCT02724852 , registered on March 31, 2016.

Keywords: HIV; MMR; Serologic response; Vaccination.

Figures

Fig. 1
Fig. 1
Flow of participants

References

    1. Litman N. Baum SG. Mumps Virus. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennette’s Principles and Practice of Infectious Diseases, 7th Edition. Pennsylvania: Churchill Livingstone Elsevier; 2010: p. 2201–2206.
    1. Gershon AA. Measles Virus (Rubeola). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennette’s Principles and Practice of Infectious Diseases, 7th Edition. Pennsylvania: Churchill Livingstone Elsevier; 2010: p. 2229–2236.
    1. Gershon AA. Rubella Virus (German Measles). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennette’s Principles and Practice of Infectious Diseases, 7th Edition. Pennsylvania: Churchill Livingstone Elsevier; 2010: p. 2127–2132.
    1. Centers for Disease Control and Prevention Progress toward global measles control and elimination, 1990–1996. MMWR. 1997;46:893–7.
    1. Centers for Disease Control and Prevention Update: global measles control and mortality reduction worldwide 1991–2001. MMWR. 2003;52:47–5.
    1. Tharmaphornpilas P, Yoocharean P, Rasdjarmrearnsook AO, Theamboonlers A, Poovorawan Y. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme. J Health Popul Nutr. 2009;27:80–6. doi: 10.3329/jhpn.v27i1.3320.
    1. History of immunization in Thailand. In: Chokpaiboonkit K, Lappra K, Mekmullika J, Narkbunnam T, Tangsathapornpong A, editors. Vaccine and immunization 2013. Nonthaburi: Ministry of Public Health; 2013. p. 13–24. (Thai)
    1. Thailand. Department of Disease Control. Bureau of General Communicable Diseases. Vaccine coverage survey, Thailand 2003. Nonthaburi: Ministry of Public Health; 2004. p. 25–31.
    1. Thailand. Department of Disease Control. Bureau of General Communicable Diseases. Vaccine coverage survey among students grade 1 and 6, 2004. Nonthaburi: Ministry of Public Health; 2005. p. 16–9.
    1. Chunharas A, Lolekha S. Immunity in children with measles vaccine: determining the proper age for booster dose. Thai J Pediatr. 1996;35:259–63.
    1. Chotpitayasunondh T, Hutagalung Y, Bock HL. Immunogenicity and reactogenecity of new live attenuated measles-mumps-rubella vaccine among Thai children. Thai J Ped. 2005;44:16–27.
    1. Reported Cases of notifiable disease by week, Thailand, 2011(2554). Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. Available from . [Cited 2011 March 27].
    1. Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med. 2006;7:467–70. doi: 10.1111/j.1468-1293.2006.00409.x.
    1. Stermole BM, Grandits GA, Roediger MP, Clark BM, Ganesan A, Weintrob AC, et al. Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults. Vaccine. 2011;29(16):2874–80. doi: 10.1016/j.vaccine.2011.02.013.
    1. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis. 2007;45:637–42. doi: 10.1086/520651.
    1. Belaunzaran-Zamudio PF, Garcia-Leon ML, Wong-Chew RM, Villasis-Keever A, Cuellar-Rodriguez J, Mosqueda-Gomez JL, et al. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine. 2009;27:7059–64. doi: 10.1016/j.vaccine.2009.09.063.
    1. Enzygnost Anti-Parotitis-Virus/IgG [package insert]. Marburg, Germany: Siemens Healthcare Diagnostics Products GnbH; 2010.
    1. Enzygnost Anti-Rubella-Virus/IgG [package insert]. Marburg, Germany: Siemens Healthcare Diagnostics Products GnbH; 2011.
    1. Enzygnost Anti-Measles Virus/IgG [package insert]. Marburg, Germany: Siemens Healthcare Diagnostics Products GnbH; 2010.
    1. Kim SS, Han HW, Go U, Chung HW. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity. Vaccine. 2004;23:290–7. doi: 10.1016/j.vaccine.2004.07.030.
    1. Lima M, De Menezes Succi RC, Nunes Dos Santos AM, Weckx LY, De Moraes-Pinto MI. Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J. 2004;23:604–7. doi: 10.1097/01.inf.0000128780.79145.5c.
    1. Fylaktou A, Haidopoulou K, Goutaki M, Papadimitriou E, Kalamitsiou S, Papaventsis D. Measles and mumps immunity in Northern Greece, 2004–2007. Euro Surveill. 2008;13(16).
    1. Molton J, Smith C, Chaytor S, Maple P, Brown K, Johnson M, et al. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect. 2010;61:73–80. doi: 10.1016/j.jinf.2010.04.004.
    1. Grabmeier-Pfistershammer K, Poeppl W, Herkner H, Touzeau-Roemer V, Huschka E, Rieger A, et al. High need for MMR vaccination in HIV infected adults in Austria. Vaccine. 2014;32:6020–3. doi: 10.1016/j.vaccine.2014.07.114.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe